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In the mature central nervous system (CNS), oligodendrocytes provide support and insulation to 
axons thanks to the production of a myelin sheath. During their maturation to myelinating cells, 
oligodendroglial precursors (OPCs) follow a very precise differentiation program, which is finely 
orchestrated by transcription factors, epigenetic factors and microRNAs (miRNAs), a class of small 
non-coding RNAs involved in post-transcriptional regulation. Any alterations in this program can 
potentially contribute to dysregulated myelination, impaired remyelination and neurodegenerative 
conditions, as it happens in multiple sclerosis (MS). Here, we identify miR-125a-3p, a developmentally 
regulated miRNA, as a new actor of oligodendroglial maturation, that, in the mammalian CNS regulates 
the expression of myelin genes by simultaneously acting on several of its already validated targets. In 
cultured OPCs, over-expression of miR-125a-3p by mimic treatment impairs while its inhibition with 
an antago-miR stimulates oligodendroglial maturation. Moreover, we show that miR-125a-3p levels 
are abnormally high in the cerebrospinal fluid of MS patients bearing active demyelinating lesions, 
suggesting that its pathological upregulation may contribute to MS development, at least in part by 
blockade of OPC differentiation leading to impaired repair of demyelinated lesions.
MicroRNAs (miRNAs) are a class of small, highly conserved, non-coding RNA molecules (approximately 21–25 
nucleotides in length) that control gene expression by binding to complementary sequences in the 3′ untranslated 
regions of their target messenger RNAs, therefore resulting in either translational repression or degradation1. 
During their biogenesis, primary miRNAs (pri-miRNAs) generate double stranded miRNA consisting of two 
arms, namely 3p and 5p, both of which can act as active mature miRNAs with distinct biological functions and 
targets2,3. These abundant, endogenous, post-transcriptional regulators are involved in important processes such 
as development, metabolism, cell proliferation, differentiation and death4. The power of this regulatory system 
relies on the unique ability of miRNAs to guide cellular processes through precise titration of gene expression, 
and on the possibility for a single miRNA to control a large number of gene products. Thus, the action of a single 
miRNA can lead to a cumulative reduction in the expression of multiple components of one specific functional 
network, and several miRNAs, transcribed in clusters, may cooperatively target various mRNAs whose protein 
products are part of the same molecular pathway5,6.
Among the most important miRNAs, the miR-125 family (miR-125a and miR-125b) has been reported to 
be implicated as either repressors or promoters in a variety of carcinomas and other diseases7. Recently, it has 
been also demonstrated that miRNAs belonging to this family are brain-enriched8 and they exert important 
roles in nervous system development. Both miR-125a and miR-125b have been shown to induce the irreversible 
commitment of human pluripotent stem cells to the neural lineage9 and glial progenitors to undertake astroglial 
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differentiation10. Despite the presence of miR-125a (in both its 5p and 3p strands) in other neural cells such as 
oligodendrocytes has been already demonstrated11,12, its role in these cells has never been investigated.
During differentiation, oligodendroglial precursor cells (OPCs) progressively increase their arborisation, 
make contacts with surrounding axons and finally produce myelin, an insulating substance wrapping axons and 
responsible for the correct transmission of the nervous impulse13. During development, OPCs arise from the 
ventricular zone in the embryonic brain and spinal cord, they proliferate and migrate through the whole paren-
chyma, and then differentiate to mature cells14. A subset of OPCs remains active throughout life, periodically 
differentiating to mature cells, thus assuring continuous myelin replacement. Each stage of differentiation can be 
identified based on the expression of typical oligodendroglial markers, among which MBP (myelin basic protein) 
is typically expressed in mature/myelinating oligodendrocytes13.
The whole differentiative program of OPCs is strictly regulated by genic and epigenetic mechanisms, including 
miRNAs15. Interestingly, in vitro interaction studies performed in HEK293 cells demonstrated that miR-125a-3p 
is able to bind and inhibit the expression of Fyn, a tyrosine kinase16 which has been implicated in axon-glial signal 
transduction and in cellular processes required for the maturation of oligodendrocytes17. Other important players 
in cytoskeletal functions and glial cell differentiation, such as the small GTPase RhoA, p38 and neuregulin 1 (Nrg-1), 
have been identified as direct targets of this miRNA18–20, suggesting that miR-125a-3p could participate in the 
regulation of oligodendroglial functions.
Here we show, for the first time, a role for miR-125a-3p in oligodendroglial differentiation. In OPCs, its 
overexpression strongly delayed oligodendroglial maturation likely due to a silencing effect on different actors 
involved in the same molecular pathways leading to myelination. Of high interest for the pathophysiology of a 
demyelinating disease like multiple sclerosis (MS), levels of miR-125a-3p were altered in the cerebrospinal fluid of 
MS patients, suggesting a link with the disease, but also a possible contribution to defective remyelination abilities 
of these patients.
Results
MiR-125a-3p potentially targets players involved in oligodendrocyte differentiation. To eval-
uate the potential relevance of miR-125a-3p in oligodendrocyte differentiation and myelination, we performed 
in silico analysis on mouse databases. First, we used MyMIR, a system that performs meta-predictions based on 
integration, filtering and re-ranking of outputs produced by different miRNA databases and we obtained a list 
of 1,673 unbiased putative target transcripts of this miRNA. Then, by using STRING, a Gene Ontology (GO) 
based tool, we found that these targets were significantly clustered in 485 GO biological processes (GO BPs; 
Supplementary Table S1), suggesting that miR-125a-3p can take part in their regulation. In agreement with pre-
vious findings that miR-125a-3p is a brain-enriched miRNA, we highlighted that many GO BPs include nervous 
system development, neurogenesis, glial cell differentiation, myelination, and oligodendrocyte differentiation 
(Fig. 1). For all of them, we calculated and reported the fold enrichment in miR-125a-3p targets (see equation (1) 
in Methods) and we found that the BPs related to oligodendrocyte differentiation have a higher enrichment 
among all the CNS-related BPs, strongly supporting our hypothesis.
Time-regulated expression of MiR-125a-3p in cultured OPCs. To assess the expression of miR-
125a-3p in the CNS, by means of real-time PCR we measured its levels in several rodent and human tissues and 
cells. Our analysis showed that indeed, miR-125a-3p it is more abundantly present in the CNS of both rat and 
human.
Figure 1. Gene Ontology biological processes (GO BPs) related to oligodendrocyte development are 
enriched in miR-125a-3p targets. Histograms in blue show the significant GO BPs enriched in miR-125a-3p 
target transcripts (fold enrichment compared to expected value = 1; see left axis). Red dots represent p-value 
(with FDR correction) of the prediction for each GO BP (see right axis; log10 scale).
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In adult rat, the highest expression was found in both total brain and spinal cord, whereas very low levels were 
found in kidney, heart, lung, stomach and liver (Fig. 2a). We performed the same analysis on human samples, and, 
among the analysed tissues, miR-125a-3p was found mainly expressed in brain tissues, with a significant enrich-
ment in frontal cortex compared to whole brain and also in brain stem and corpus striatum (Supplementary Fig. S1). 
In line with the rodent data, lower expression levels were found in kidney and liver, confirming the brain enrichment 
of this miRNA. Then, we asked whether miR-125a-3p is regulated in rat developing brain. To this aim, we collected 
RNA from total rat brain at different ages starting from embryonic day 14 (E14) to adulthood (6 months of age). 
Levels of miRNA were already high at E14, gradually declined up to postnatal day 0 (P0), remained low after 
birth up to P5, increased immediately before myelination onset and then remained mostly stable until adulthood 
(Fig. 2b).
To evaluate the distribution of this miRNA in the different neural cell types during brain development, we 
took advantage of in situ hybridization (ISH) in combination with immunohistochemistry for cell markers, 
namely Nestin for multipotent neural stem cells, NeuN for neurons, GFAP for astrocytes, Olig2 for oligodendro-
cytes and Iba1 for microglia. In embryonic brain, miR-125a-3p was found widespread in the whole parenchyma 
with a higher signal in the ventricular zone (Fig. 2c), where it mostly co-localized with Olig2, which, at this stage, 
labels a pool of precursor cells that will give rise to both OPCs and neurons21, and to a lower extent with Nestin. 
In postnatal brain, the expression of miR-125a-3p is restricted to neurons, both in cortex and striatum, and oli-
godendrocytes (Fig. 2c), whereas only a few cells also expressed GFAP and no apparent co-localization was found 
with microglia.
Then, we focused on oligodendrocytes, and evaluated whether miR-125a-3p is preferentially expressed in early 
OPCs expressing the proteoglycan NG2, or in more mature CC1+ oligodendrocytes. To this aim, we performed 
a triple immunofluorescence staining using the same ISH technique described above for miR-125a-3p in parallel 
with anti-NG2 and anti-CC1 antibodies in both postnatal (P7) and adult brains, in particular, corpus callosum, 
where a large number of oligodendrocytes could be analysed. In postnatal brain, some cells already expressed 
CC1 and virtually all of them were also decorated with the probe for miR-125a-3p (Fig. 2d). As expected, the 
number of CC1+ cells in the adult brain was much higher, but also in this case, virtually all cells expressed miR-
125a-3p. Both in P7 and adult brains, co-localization between miR-125a-3p and NG2 was also found, but only in 
a subpopulation of cells, with a further trend toward a decrease in the adult, suggesting that miR-125a-3p serves 
a more critical function in mature oligodendrocytes.
Then, to assess if the expression timing of miR-125a-3p indeed changes during oligodendrocyte maturation, 
we used cultured OPCs to measure its expression during their in vitro differentiation. Interestingly, the levels 
of miR-125a-3p progressively increased in OPCs kept in cultures under differentiating conditions with the tri-
iodothyronine hormone (T3), reaching a 2.5-fold increase after 6 days (Fig. 2e) compared to the initial proliferat-
ing conditions (day 0, in the presence of growth factors and in the absence of T3).
Globally, the in vivo and in vitro data suggest multiple developmental roles for miR-125a-3p, that, during 
embryonic life, is expressed at high levels in neural undifferentiated precursors likely to prevent their untimely 
commitment, and that, within cells of the oligodendroglial lineage, it could crucially regulate maturation by 
repressing early transcripts important for the maintenance of OPCs at an undifferentiated state.
Since we were interested in myelination, we investigated more in detail the possible role of miR-125a-3p dur-
ing physiological differentiation of OPCs to mature oligodendrocytes.
Over-expression of miR-125a-3p by mimic treatment impairs while its inhibition with an 
antago-miR stimulates oligodendroglial maturation. When OPCs are cultured in the absence of 
growth factors and in the presence of the T3 hormone, they undergo rapid in vitro differentiation, whose phases 
can be easily monitored by staining cells for progressively more mature oligodendrocyte markers (drawing in 
Fig. 3).
To evaluate the possible role of miR-125a-3p in OPC differentiation, we overexpressed it by transfecting cells 
with a specific miR-125a-3p mimic the same day of growth factors withdrawal (corresponding to day 0 in Fig. 2e) 
when the endogenous levels of miR-125a-3p were low. Then, we performed immunofluorescence stainings for the 
myelin basic protein (MBP), a typical marker of mature oligodendrocytes and counted cells in mimic-transfected 
cultures and in control conditions (i.e., cells transfected with the corresponding negative mimic). Two days after 
miR-125a-3p mimic transfection, the number of MBP+ cells was strongly reduced compared to controls, sug-
gesting an effect on terminal maturation (Fig. 3a–c). Since MBP is not present in the list of miR-125a-3p putative 
targets obtained from MyMIR, we reasoned that miR-125a-3p inhibitory effect is likely exerted on upstream play-
ers in the pathway culminating with OPC maturation and MBP expression. Thus, we also counted cells positive 
for earlier oligodendroglial players, such as, sequentially, GPR17 (a marker of early precursors and intermediate 
immature oligodendrocytes)22,23, O4 (a marker of immature oligodendrocytes)24, and the microtubule associated 
protein MAP1B25 (that labels a slightly more advanced differentiation stage compared to O4, see drawing in 
Fig. 3). While the number of cells positive for GPR17 and O4 were unaltered (Fig. 3d,e), the number of MAP1B+ 
cells was reduced by approximately the 50% after mimic miR-125a-3p treatment (Fig. 3f), suggesting inactiva-
tion of transcripts specifically involved in the progression between the O4 and the MAP1B stage. To confirm 
the importance of miR-125a-3p in OPC maturation, in a parallel experiment, OPCs maintained under the same 
culture conditions were transfected with a hairpin inhibitor RNA that specifically inactivates miR-125a-3p. A 
marked increase in the number of MBP+ cells was found, yet with no significant effect on the number of GPR17+ 
cells (Fig. 3g,h). Globally, these data suggest that miR-125a-3p exerts a silencing effect on transcripts typical of 
OPC differentiation stages that are upstream to MAP1B but downstream to GPR17 and O4.
Then, we wondered whether mimic overexpression in cultured OPCs maintained under slower differentiating 
conditions could also affect the expression of these earlier transcripts.
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To test this hypothesis, we cultured OPCs in the absence of both growth factors and T3. Under these set-
tings, OPCs did undergo spontaneous differentiation in culture, but did not reach terminal maturation within 
Figure 2. Expression of miR-125a-3p in physiological conditions. (a) miR-125a-3p relative expression 
was analyzed using Taqman assay in different rat tissues and compared to level measured in brain. Neural 
tissues showed higher expression with respect to other tissues. Data were expressed as mean ± SEM, n = 3; 
two-tailed unpaired t test *p < 0.05, **p < 0.01, ***p < 0.001 vs. total brain. (b) The levels of miR-125a-3p were 
analyzed during rat brain development and normalized to the levels at P0. Data were expressed as mean ± SEM, 
n = 4 animals for each time-point; one-way ANOVA with Dunnett’s post-test ***p < 0.001 vs. P0. (c) In situ 
hybridization of miR-125a-3p (red fluorescence) in combination with different lineage markers during rat 
brain development from embryonic day 14 (E14) to adulthood. In embryonic brain the ventricular zone (vz) 
was chosen. In postnatal brain neurons stained with NeuN were shown in cerebral cortex (cx), whereas Olig2+ 
oligodendrocytes were shown in corpus callosum (CC). Iba1 and GFAP were shown in triple stainings (white 
pseudocolor) to identify microglia and astrocytes, respectively. (d) In situ hybridization of miR-125a-3p (in red) 
in double staining with both NG2 (early OPC marker; in green), and CC1 (marker of mature oligodendrocytes; 
in blue). Micrographs show representative pictures of corpus callosum of P7 rats (upper panels) and adult 
rats (lower panels). White arrows highlight co-localization of miR with NG2, while yellow arrows refer to co-
localization with CC1. (e) Time-course of mir-125a-3p expression in OPCs was analyzed in differentiating 
conditions and normalized to the levels in undifferentiated OPC (day 0). MiR-125a-3p levels progressively 
raised, reaching a 2.5-fold increase after 6 days in culture. Data were expressed as mean ± SEM, n = 6; one-way 
ANOVA with Dunnett’s post-test; *p < 0.05, **p < 0.01 vs. day 0.
www.nature.com/scientificreports/
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Figure 3. Effect of over-expression or inhibition of miR-125a-3p during oligodendroglial differentiation. 
To evaluate the time-dependent effects of either the overexpression or the silencing of miR-125a-3p on OPC 
maturation 4 different markers of progressive differentiation stages were analysed by immunocytochemistry, 
GPR17 and O4 (which label pre-oligodendrocytes), MAP1B (which labels a slight more advanced stage) 
and MBP (which labels terminally differentiated cells). Cells were stained for the selected markers 48 h 
after transfection of miR-125a-3p mimic or inhibitor, in the presence or in the absence of the T3 hormone. 
(a–h) The drawing represents a schematic timeline of the fast differentiation protocol in the presence of 
T3, showing the presented markers. (a,b) Representative micrographs of MBP+ oligodendrocytes after 
transfection of miR-125a-3p mimic in presence of T3 were shown. (c–f) Histograms show the changes in the 
number of cells positive for MBP (n = 10), GPR17 (n = 8), O4 (n = 2) and MAP1B (n = 3) with respect to 
negative controls. Data were expressed as mean ± SEM, two-tailed unpaired t test *p < 0.05, ***p < 0.001 vs. 
negative control. (g,h) Transfection of OPC with the inhibitor of miR-125a-3p (in presence of T3) led to a 
significant increase in the number of MBP+ (n = 4; p-value = 0.0376), but not GPR17+ (n = 7) cells. Data 
were expressed as mean ± SEM, two-tailed unpaired t test *p < 0.05 vs. negative control. (i–l) A second 
differentiation protocol in the absence of T3 (slower protocol) was used. Also in this case, the drawing 
represents a schematic timeline showing the presented markers. (i,j) Representative micrographs of GPR17+ 
oligodendrocytes after transfection of miR-125a-3p mimic in absence of T3 were shown. (k,l) Histograms 
show a considerable decrease in the number of GPR17+ (n = 7) and MAP1B+ (n = 3) cells after transfection 
with the mimic in the absence of T3 with respect to the negative control. Data were expressed as mean ± SEM, 
two-tailed unpaired t test *p < 0.05 vs. negative control.
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the experimental observation times, thus representing a useful paradigm for our purpose (see drawing in Fig. 3). 
As expected, under this culturing protocol, almost no MBP+ cells were detected; however, upon mimic overex-
pression, the number of both GPR17+ cells and of MAP1B+ cells were strongly reduced (of − 60% and − 35%, 
respectively, Fig. 3i–l) compared to controls. Representative micrographs of OPCs transfected with mimic and 
stained with the selected markers are shown in Supplementary Fig. S2.
These data demonstrate that if differentiation proceeds at a lower speed, miR-125a-3p can also act on early 
targets, whereas, if differentiation is faster, miRNA can only act on later transcripts that are closer to terminal 
maturation.
These data also suggest that the post-transcriptional regulation of genes involved in oligodendrocyte matura-
tion vary depending on basal or stimulated conditions such as those occurring upon CNS damage, when recruit-
ment and differentiation of OPCs is rapidly and markedly improved to sustain myelin repair26.
MiR-125a-3p acts on multiple target transcripts involved in oligodendrocytes maturation. 
Based on the current knowledge, a single miRNA can interact with hundreds of target transcripts with “imperfect 
matches”; this unique feature enables a fine titration of several players of the same pathway at the same time. 
Since, as mentioned above, Mbp is not a predicted target for miR-125a-3p, we used QIAGEN’s Ingenuity Pathway 
Analysis tool (IPA®, QIAGEN Redwood City, www.qiagen.com/ingenuity) to evaluate how alterations of already 
validated targets of the myelination pathway such as Smad4, Fyn, RhoA, p38 and Nrg19,16,18–20 could potentially 
influence MBP expression, thus being responsible for the observed delay in oligodendroglial maturation. This 
analysis showed that not only Nrg1 and Fyn, but also RhoA and p38 (that are downstream targets of FYN sign-
aling)27,28 can directly or indirectly promote MBP expression, suggesting that miR-125a-3p may limit oligoden-
droglial maturation through inhibition of some of these targets, if not all (Fig. 4a). The list of all the mentioned 
targets is reported in Table S2 along with their validated interactions. To confirm this hypothesis, we performed 
quantitative real time PCR experiments after miR-125a-3p over-expression in OPCs, and found that the expected 
reduction of Mbp mRNA was also accompanied by considerable downregulation of both Fyn, Nrg1 and Map1b 
(Fig. 4b).
MiR-125a-3p is up-regulated in cerebrospinal fluid of MS patients. MiRNAs are stable in body 
fluids and their alterations in plasma and cerebrospinal-fluid (CSF) may represent novel biomarkers for the diag-
nosis and prognosis of human diseases. It has been proposed that circulating miRNAs are originated by passive 
leakage from broken cells, thus reflecting the disease state of injured tissues29. Since progressive loss of the ability 
of OPCs to generate mature oligodendrocytes is a well-known feature of both human MS and other demyelinat-
ing diseases30, we wondered whether miR-125a-3p were also altered in the CSF of MS patients. We thus measured 
miR-125a-3p levels in CSF samples from 30 MS patients (28 patients with the relapsing-remitting and 2 with the 
secondary-progressive form), 11 of which had clinically or neuroradiologically active disease (active lesions) at 
the time of CSF withdrawal. We compared MS patients to a control group mainly encompassing non-Alzheimer 
dementias and normal pressure hydrocephalus patients, and to a pure Alzheimer’s patients group (AD) 
(the demographic data of patients are summarized in Table 1). Quantitative real-time PCR analysis revealed a sig-
nificant upregulation (up to 4 fold) of miR-125a-3p in the active MS group compared to both healthy subjects, AD 
and inactive MS groups (Fig. 5; p = 0.004 vs. controls; p = 0.004 vs. AD; p = 0.0545 vs inactive MS; Unpaired t test). 
Applying One-way ANOVA to consider multiple comparisons, active MS was still significantly different from 
the control group (p = 0.02). Although these findings are obviously not sufficient for proposing miR-125a-3p as a 
biomarker for MS, our results indeed suggest its potential clinical relevance in this disease.
Figure 4. Model representing the connections between miR-125a-3p and MBP. (a) In this model we 
reconstructed a network showing how miR-125a-3p can influence MBP expression, starting from predicted 
(Map1b) and validated targets of this miRNA (Smad4, p38, RhoA, Nrg1 and Fyn). All these direct targets 
converge in a pathway leading to the maturation of oligodendrocytes. (b) To confirm this mechanism we 
performed qPCR experiments after miR-125a-3p over-expression in OPCs and we found that both Fyn (n = 3), 
Nrg1 (n = 3), Map1b (n = 3) and in turn Mbp (n = 5) mRNA were strongly down-regulated in these conditions. 
Data were expressed as mean ± SEM, two-tailed unpaired t test *p < 0.05 vs. negative control = 100.
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Discussion
Several papers have described the miR-125 family (composed by miR-125a and 125b) as a mostly important one 
for its implication in cancer7. Only recently, the role of miR-125a has been investigated also under physiological 
settings, when a fine balance between proliferation and differentiation is responsible for cell lineage commitment. 
However, studies in the literature did not analyze separately the specific role of either the − 5p and the − 3p strand, 
since they often refer to miR-125a as the double-stranded precursor miRNA9,10, and this may be misleading. 
Despite previous studies demonstrating its presence in oligodendrocytes, with higher abundance of the − 3p com-
pared to the − 5p strand11, no functional roles for this miRNA in these cells had been yet demonstrated. Here, we 
describe miR-125a-3p as a new regulator of oligodendroglial differentiation with potential roles in myelination 
and in defective remyelination. First, our gene ontology based study showed that several of the predicted target 
mRNAs of this miRNA are involved in nervous system development, with higher enrichment in glial cell differ-
entiation, myelination, axon ensheathment and oligodendrocyte differentiation (up to 4-fold).
Then, we show that, both in rodents and humans, miR-125a-3p is more abundantly expressed in CNS with 
respect to peripheral tissues, with a higher expression in neurons and oligodendrocytes. Our expression studies 
during brain development showed very high levels of miR-125a-3p at embryonic day E14, mainly in neural pre-
cursors. This is in line with previous literature data demonstrating that miR-125a directly binds Smad4, a key 
regulator of pluripotent stem cell lineage commitment, thus potentiating early neural specification9. Moreover, 
during postnatal life, SMAD4 and its cascade inhibit oligodendrogenesis by inducing the Id and Hes genes and 
by repressing Olig1 and Olig231. Interestingly, by means of in situ hybridization, we found that miR-125a-3p is 
expressed throughout post-natal age in Olig2+ oligodendrocytes, suggesting that, in these cells, it is necessary for 
silencing SMAD4, in order to promote the expression of these genes and subsequent oligodendroglial specifica-
tion. Several miRNAs have been demonstrated to regulate the transition from neural stem cells to mature oligo-
dendrocytes. Indeed, as OPCs differentiate, the levels of several miRNAs including miR− 138, − 219 and − 338 
increase and promote maturation through the inhibition of repressors of oligodendrocytes differentiation, such 
as Hes5, Sox6, Foxj3, and of genes that promote OPC proliferation, such as Fgfr2 and Pdgfrα 32,33. In line with the 
hypothesis of the modulation of early targets, during in vitro OPC differentiation miR-125a-3p is progressively 
up-regulated (Fig. 2e). Almost all mature oligodendrocytes, positive for CC1 express miR-125a-3p, whereas only 
Diagnostic group n Sex F:M Age y, mean
miR-125a-3p  
log2 fold increase p-value
CTRL 13 1.6 75.9 0.000 ± 0.141 —
AD 17 2.4 72.6 0.030 ± 0.125 0.731
Active-MS 11 1.75 32.1 0.700 ± 0.185 0.004
Inactive-MS 19 3.75 34.8 0.152 ± 0.178 0.452
Table 1.  Demographic data and miR-125a-3p log2 fold increase by diagnostic group. P-values were 
obtained applying unpaired t-test compared to control group.
Figure 5. Expression of miR-125a-3p in the cerebrospinal fluid of MS patients. A significant increase in 
the relative expression of miR-125a-3p was found by RT-PCR in the cerebrospinal fluid of active MS patients 
(n = 11) compared to control (C; n = 13; p value = 0.004), Alzheimer (AD; n = 17; p value = 0.004) and inactive 
MS (n = 19; §p = 0.0545) groups. Data were expressed as mean ± SEM; *p ≤ 0.05, **p < 0.01 Unpaired t test.
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a subset of NG2+ cells express it (Fig. 2d), suggesting a role in the repression of early genes when oligodendro-
cytes become mature and/or myelinating.
The recent literature demonstrated that a single miRNA can regulate hundreds of transcripts, thus having a 
very broad array of functional consequences34. Thus, integration of the information on all the validated targets of 
a given miRNA can shed light on very complex regulatory networks similar to those of transcription factors. In 
this respect, our data on the role of miR-125a-3p on OPCs maturation under “strong” or “mild” differentiation 
paradigms unveil that myelination may be regulated in different ways even by the same miRNA depending upon 
distinct pathophysiological conditions. Specifically, to identify the targets of miR-125a-3p during OPC differen-
tiation in vitro, we took advantage of 4 different markers that identify 4 distinct sequential stages of OPC differ-
entiation, namely: GPR17, O4, MAP1B, and MBP (Fig. 3). Of these, GPR17 is a new oligodendroglial marker 
expressed in early OPCs up to the stage of immature pre-oligodendrocytes22 and now widely adopted to specifi-
cally label OPCs at an intermediate differentiation stage partially overlapping with O4 (Fig. 3; refs 23, 35–38). O4 
is instead a well-established marker of immature oligodendrocytes39. MAP1B is the major microtubule associated 
protein found in microtubules early during development40. In oligodendrocytes, MAP1B expression is slightly 
delayed compared to O4 and immediately precedes morphological differentiation, after which MAP1B is strongly 
down-regulated41. Finally, MBP is known to label mature oligodendrocytes, being a protein associated to myelin42. 
When miR-125a-3p was overexpressed by mimic transfection in the presence of T3 (“strong” differentiation 
protocol), block of terminal maturation was accompanied only by a strong reduction of MAP1B and MBP expres-
sion, whereas earlier markers were not affected. When miR-125a-3p overexpression was performed using the 
“mild” differentiation protocol (i.e., in the absence of T3), OPCs proceeded slower along their lineage and late 
antigens were not visible, but the number of earlier GPR17+ and MAP1B+ precursors was also diminished, to 
suggest that, under these conditions, miR-125a-3p can regulate OPC maturation not only downstream but also 
upstream to GPR17.
These data show that when miR-125a-3p levels are high, oligodendrocyte maturation is blocked, and this 
could explain the high expression levels found during embryogenesis, to suggest that miR-125a-3p may, at the 
same time, promote neural specification and prevent the untimely expression of genes necessary for oligoden-
drocyte commitment/maturation and the subsequent myelination process that, indeed does not take place at this 
stage. Globally these findings show that the biological role of miR-125a-3p changes depending on the develop-
mental stage, and that, from embryonic life to adulthood, its expression moves from brain ventricles to paren-
chyma up to neurons of the cerebral cortex, where it is likely to repress the expression of non-neuronal genes.
Several other transcripts involved in pathways other than myelination have been so far identified as direct 
targets of miR-125a-3p. By using the Ingenuity Pathway Analysis tool, we have been able to connect several 
of these players to each other, building a model for the synergic regulation of MBP and myelination (Fig. 4). 
Among these players, FYN-kinase plays important roles in neuronal functions, myelination, oligodendrocytes 
formation and cytoskeletal rearrangements43. NRG1 is a potent chemoattractant that selectively regulates OPC 
migration during early CNS development stages of CNS through interaction with the ErbB4 receptor44. In line 
with the prediction of our IPA analysis, overexpression of miR-125a-3p resulted in a reduction of Fyn and Nrg1 
and Map1b. It is worth to note that despite a striking effect on MBP expression, the reduction of these genes was 
quantitatively smaller, supporting the hypothesis that the mechanism of action consists in a fine modulation of a 
network of genes. Indeed, several reports, in which physical interaction between a miRNA and specific binding 
sites on target transcripts have been demonstrated by 3′UTR reporter assay, showed a 20% reduction of the target 
mRNA45. It is also worth to note that miRNAs do not necessarily degrade their target mRNAs, but they can also 
impair their translation into protein46, thus, the downregulation observed by qRT-PCR may not fully reflect the 
observed functional effect.
These data are also consistent with the previous demonstration that the mRNAs of both Map1b and Mbp are 
stabilized by the RNA-binding protein QKI, which is, in turn, regulated by FYN-Kinase. Lack of FYN-kinase, as 
detected after mimic transfection, leads to failure of MBP to incorporate into myelin17. Moreover, FYN activation 
is mediated by phosphorylation of a tyrosine residue (Y420), which, in turn, depends on the interaction between 
NRG1 (which is downregulated after mimic transfection) and its receptor ERBB447. All these data support the 
hypothesis that miR-125a-3p synergistically inhibits different mechanisms that normally promote the expression 
of myelin genes. Thus, it is not surprising that miR-125a-3p can strongly impair myelination via the forced inhi-
bition of multiple targets.
The identification of miR-125a-3p as a modulator of oligodendrocyte differentiation provide new findings 
about the complex regulation of myelination processes and it is conceivable that an antago-miRNA specific for 
this miRNA may help in promoting oligodendrocyte maturation in diseases characterized by impaired myelin 
repair.
Reports from oncology, cardiovascular research and infectivology have demonstrated the potential diagnostic 
and prognostic significance of miRNAs passively leaked or actively released from cells into biological fluids 
including circulating blood and CSF29, either contributing to disease pathogenesis or reflecting response to treat-
ment. Living neurons, but also oligodendrocytes and other CNS cells secrete miRNAs into the extracellular space 
packaged in exosomes or microvesicles48,49. Recent evidence support that miRNAs are altered in bodily fluids in 
Parkinson’s and Alzheimer’s Disease50, suggesting that their release does reflect not only activation of immune 
cells, but also the undergoing neurodegenerative process.
In a previous study, the -5p arm of miR-125a was found to act as a key regulator of brain endothelial integrity 
and its levels to be increased in MS brain lesions as compared to surrounding normal appearing white matter51. 
Coherently, treatment of MS patients with the anti-VLA4 monoclonal antibody (Tysabri) that inhibits inflam-
matory cell migration to the brain parenchyma and thus favours endothelial integrity, results in decreased blood 
levels of miR-125a-5p52. However, up to the present study, changes of the − 3p arm of this miRNA had not been 
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investigated. Here we show that miR-125a-3p is up-regulated in the CSF of relapsing MS patients compared to 
control subjects. This alteration was specific for MS, since it was not found in Alzheimer’s disease patients.
This increase could be explained by passive release of miR-125a-3p from neural cells such as neurons or oligo-
dendrocytes undergoing destruction in active MS patients. We cannot obviously exclude that the aberrant pres-
ence of this miRNA in CSF could also reflect the inflammation state of the CNS during the relapsing-remitting 
phase of the disease53, since previous reports have demonstrated the role of miR-125a in immune cells activation54.
Here we propose a mechanistic role for miR-125a-3p based on data obtained on cultured rodent OPCs. We 
are aware that human OPCs do not necessarily behave in the same exact way, since they are very heterogeneous 
and only some subsets are able to myelinate. Some miRNAs thought to be characteristic of human OPCs are also 
present in mature oligodendrocytes, suggesting that after differentiation, they may acquire different roles, such as 
regulation of plasticity for myelin maintenance and repair55. For example, miR-138, which is known to be more 
expressed in mature oligodendrocytes compared to OPCs, induces oligodendrocyte differentiation and expres-
sion of CNP and MBP, but in contrast, its sustained expression can lead to a reduction in MOG protein, demon-
strating that miRNAs may have opposite effects during the transition from OPCs to mature oligodendrocytes56. 
In this respect, our results suggest that also miR-125a-3p could have a Janus-like role in OPC maturation, acting 
as a repressor in the early phases of the maturation and likely as a positive factor in later phases, repressing genes 
that could impair terminal maturation.
Heterogeneity of OPCs will have to be taken in account also when transposing our in vitro results to human 
MS subjects showing increased levels of miR-125a-3p in CSF; however, this does not invalidate the biologi-
cal importance of our findings in MS patients, since a biomarker is defined as a proxy that allows remote and 
early detection of a biological process (i.e., disease) regardless of its mechanistic role in the condition being 
diagnosed57. In this perspective, our data could serve as a basis for further studies on larger cohort of patients to 
validate miR-125a-3p as a biomarker for different stages of MS, providing a previously unrecognized venue for 
medical interventions.
Methods
In silico analysis. For the prediction of miRNA target transcripts we used MyMir58 (http://www.itb.cnr.it/
micro), a system based on integration, filtering and re-ranking of outputs produced by different miRNA data-
bases (i.e. TargetScan, RNAHybrid, miRanda, PITA). STRING database59 was used to obtain a list of the Gene 
Ontology60 biological processes (GO BPs) significantly enriched (p value < 0.05) for miR-125a-3p targets. For the 
analysis, the false discovery rate (FDR) adjusted p-value was used, to reduce the chance of false-positive results. 








m = genes target in a BP; n = all genes target in the list; M = all genes in a BP; N = all genes in the genome. A fold 
enrichment greater than 1 (expected value) indicates that the category is overrepresented in the input list. The 
network model for the synergic regulation of MBP was built with QIAGEN’s Ingenuity® Pathway Analysis (IPA® , 
QIAGEN Redwood City, www.qiagen.com/ingenuity), by inserting both miR-125a-3p predicted and validated 
targets.
Primary cultures and OPC isolation. Mixed glial cultures were obtained from 12 postnatal day 2 (P2) 
Sprague-Dawley rat cerebral cortices pooled together. The shaking protocol allowed the sequential isolation of 
OPCs, astrocytes and microglia from the same preparation62. In these conditions we obtained approximately 
600,000 OPCs from each pup; contaminating astrocytes and microglia were routinely less than 2–3% each.
OPCs were plated onto poly-D,L-ornithine-coated (final concentration 50 μ g/ml; Sigma-Aldrich) 13-mm glass 
coverslips for immunocytochemistry (2–3 × 104 cells/coverslip) and poly-D,L-ornithine-coated 6-wells plates 
(105 cells/coverslip) or 6-cm dishes (2.5 × 105 cells/coverslip) for qRT-PCR assays. Cells were plated in Neurobasal 
medium supplemented with 2% B27 (Life Technologies), 2 mM L-glutamine, 10 ng/ml human platelet-derived 
growth factor BB (Sigma-Aldrich), and 10 ng/ml human basic fibroblast growth factor (Life Technologies) to 
promote proliferation. When OPCs reached a 60% confluency, cultures were switched to a Neurobasal medium 
lacking growth factors and containing triiodothyronine 15 nM (T3, Sigma-Aldrich) to allow differentiation. In 
selected experiments, T3 was not added to induce a slower maturation.
The primary cultures used for the experiments were derived from rats. All the procedures were performed in 
accordance with the approved national law, with the implementation of European Union Directive nr. 86/609/
CEE regarding the Protection of animals used for experimental research.
The experiments were approved by the Council of the Dipartimento di Scienze Farmacologiche e 
Biomolecolari, Università degli Studi di Milano, Italy, which is legally entitled for the use of animals for scientific 
proposes (D.M. of Italian Ministry of Health, Authorization #295/2012-A 12/20/2012, according to the D.lgs 
116/92).
Transfection of primary OPCs with miR-125a-3p mimics and inhibitors. OPCs were transfected 
immediately after switching from proliferating to differentiating medium (in the absence or in the presence 
of T3). MiR-125a-3p mimics or hairpin inhibitors (Dharmacon) were transfected at the final concentration 
of 50 nM. A scrambled miRNA transfection was included as negative control. MiRNAs were transfected with 
Lipofectamine RNAiMAX reagent (Life Technologies) following the manufacturer’s protocol.
Immunocytochemistry and cell counting. Cells were fixed in a 4% paraformaldehyde phosphate-buffered 
solution containing 4% sucrose. The following primary antibodies were used: rabbit anti-Olig2 (1:100; Millipore), 
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rabbit anti-GPR17 (1:100; Cayman Chemical), rat anti-MBP (1:200; Merck Millipore), goat anti-MAP1B (1:300; 
Santa Cruz), mouse anti-O4 (1:100; R&D), mouse anti-GFAP (1:100; Cell Signaling). To identify microglial 
cells, coverlips were incubated with isolectin B4 FITC conjugated (1:100; Sigma). Incubation of primary anti-
bodies were performed 2.5 hours at room temperature or over-night at 4 °C. Cells were then incubated for 1 h at 
room temperature with secondary antibodies conjugated to either AlexaFluor 488 or AlexaFluor 555 (1:600; Life 
Technologies). All the antibodies were diluted in a phosphate-buffered blocking solution (pH 7.4) containing 
0.3% Triton X-100, with the exception of O4, which did not require detergents. Nuclei were labeled with the 
UV fluorescent dye Hoechst 33258 (1:10,000; Life Technologies). Coverslips were then mounted in a fluorescent 
mounting medium (Dako). Olig2+ cells were considered as oligodendroglial cells (see Supplementary Figs S2 
and S3 for representative micrographs). Positive cells for the selected markers were counted from 20 random 
fields for each coverslip (0.07 mm2/field). The result was expressed as a percentage over the number of nuclei, 
and then normalized versus controls (transfected with negative miRNA) set to 100%. In the presence of T3, in 
control conditions, we counted a mean of 880 nuclei, 124 GPR17+, 330 O4+, 282 MAP1B+ and 54 MBP+ cells for 
each coverslip. In the absence of T3, in control conditions, we counted a mean of 848 nuclei, 138 GPR17+ and 217 
MAP1B+ cells for each coverslip.
MicroRNA in situ hybridization (ISH) in combination with immunohistochemistry. After anes-
thesia, post-natal P7, P14 and adult rats were perfused with 4% paraformaldehyde (PFA; Sigma) in phosphate 
buffered saline (PBS). Brains were explanted and post-fixed in 4% PFA for 1 hour. Embryos and P2 rat brains were 
fixed by immersion in 4% PFA for 4 hours. Tissues were washed in PBS, dehydrated overnight in 30% sucrose, 
and then embedded in OCT (Bio-optica). Twelve micrometer sections were cut on a cryostat in RNase-free con-
ditions, transferred to Superfrost/plus microscope slides (Thermo Scientific), and stored at 20 °C. Buffers and 
reagents were prepared using DEPC-treated (Sigma) water and autoclaved. Detection of miRNA was performed 
with miRCURY LNA miRNA detection probes (Exiqon), using a previously described protocol63 with minor 
modifications. Briefly, tissues were further fixed in 10% formalin (Sigma) and then subjected to acetylation. 
Pre-hybridization was carried out for 2 hours at room temperature, followed by hybridization with scramble/miR-
125a-3p DIG-LNA probes (20 nM; Exiqon) overnight at 55 °C. The following day, endogenous peroxidases were 
blocked with 1% H2O2 (Sigma). For probe detection, the sections were incubated with a sheep anti-DIG-POD 
primary antibody (1:600; Roche), diluted in blocking buffer (0.05% Tween-20, 1% BSA and 1% sheep serum, all 
from Sigma) at room temperature for 2 hours, then with biotynilated-tyramide for signal amplification (Perkin 
Elmer) and finally streptavidin Alexa Fluor 555 conjugated (1:1000; Life Technologies) for 50 minutes.
For detecting the epitopes of interest, immunohistochemistry (IHC) was combined with ISH by using 
the following primary antibodies: rabbit anti-Olig2 (1:100; Millipore), rabbit anti-Iba1 (1:500; Wako), mouse 
anti-GFAP (1:100; Cell Signaling), mouse anti-NeuN (1:100; Millipore), mouse anti-Nestin (1:100; Millipore), 
rabbit anti-NG2 (1:100; Millipore), mouse anti-CC1 (1:50; Calbiochem). Alexa Fluor 488 or 633 (1:600 and 1:300, 
respectively; Life Technologies), were used as secondary antibodies in double or triple staining. Stainings with 
Alexa Fluor 633 were always shown in either white or blue pseudocolor. Nuclei were labeled with the UV fluo-
rescent dye Hoechst 33258 (1:20,000; Life Technologies). Finally, slides were mounted in a fluorescent mounting 
medium (Dako).
Total RNA extraction, retrotranscription and gene expression analysis. Total RNA was extracted 
from cells or tissues using Trizol reagent (Life Technologies). RNA from neural cells was harvested from 
in vitro cultures (see above). RNAs from human tissues were purchased from Ambion. For qRT-PCR of miRNA, 
10 ng of total RNA was reverse-transcribed with TaqMan® MicroRNA Reverse Transcription Kit and then 
subjected to Taqman microRNA assay (Life Technologies). Expression level of miR-125a-3p was normalized 
to the U87 snRNA in rat and to the U6 snRNA in human by the Δ Ct method. For gene expression analysis, 
cDNA synthesis was performed starting from 800 ng of total RNA using SuperScript® II Reverse Transcriptase 
(Life Technologies). The expression of all genes was analyzed with TaqMan® Gene Expression Assays and normal-
ized to GAPDH expression using CFX96 real time PCR system (Bio-rad) following the manufacturer’s protocol.
Isolation of miRNAs from cerebrospinal fluid (CSF) and real-time PCR quantification assays. 
Human samples of CSF have been obtained from the Institute of Experimental Neurology (INSpe) Biobank at the 
San Raffaele Hospital after thorough evaluation of neuropathology and consisted of MS, Alzheimer, and neuro-
logically normal control subjects. The distinction between patients who had radiologic or clinical evidence of MS 
activity was done through the assessment of gadolinium-enhancing lesions on cranial MRI and presence of recent 
clinical relapses64. According to the recently updated McDonald criteria65, patients have been considered to be 
in a clinical relapsing phase of the disease if they experienced a relapse in the 30 days prior to lumbar puncture. 
Patients with one or more gadolinium-enhancing lesions at baseline MRI (with or without corresponding clinical 
symptoms) were classified the same as in a relapsing (active) phase of the disease.
The specimens were collected from adult subjects under informed consent in accordance with the laws and 
with the internal guidelines and regulations of the San Raffaele Hospital. The protocols were approved by the 
Ethical commitee of the San Raffaele Hospital. The analysis on human specimens were also approved by the 
Ethical Committee of the University of Milan (prot. 71/14). CSF samples were collected by diagnostic lumbar 
puncture or puncture of Ommaya reservoirs from individual MS patients, centrifuged at 13,000 g for 5 minutes 
and stored at − 80 °C. RNA was isolated from 200 μ l of CSF using miRNeasy Serum/Plasma Kit (Qiagen, Milan) 
following the manufacturer’s protocol and reverse-transcribed with TaqMan® MicroRNA Reverse Transcription 
Kit (Life Technologies). Expression level of miR-125a-3p was analyzed with TaqMan® MicroRNA Assays and 
normalized to spiked-in cel-miR-39 by the Δ Ct method.
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Statistical analysis. Data are presented as mean ± standard error (SEM) of replicates. GraphPad Prism 6.0 
was used for statistical analysis. For all comparisons between two groups with a normal distribution, two-tailed 
unpaired t-test was performed. For multiple comparison testing, one-way analysis of variance (ANOVA) accom-
panied by Dunnett’s post-hoc test were used. For CSF samples, data with a Median Absolute Deviation (MAD) 
> 3.5 were considered outliers and discarded from the analysis. P values < 0.05 were considered statistically 
significant.
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